Skip to main content
1-featuredimage

Welcome to hubXchange's Antibody Therapeutics Xchange New Jersey 2026.

This event brings together senior-level scientists and executives from the pharmaceutical and biotech sectors to tackle key challenges in Lead Identification & Optimization, Formats & ScaffoldsBi/MultispecificsADC Linker Design & Conjugation Technologies, and ADC Cytotoxic Payload

Attendees can engage in roundtable discussions, pre-booked 1:1 meetingspresentations, and networking sessions with top industry experts, to foster collaboration and find innovative solutions to accelerate antibody therapeutics.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking.

New Jersey | Tuesday 3rd November 2026 | 08:00am - 05:45pm

 VIEW AGENDA    REGISTER FOR FREE    OUR PARTNERS    EVENT INFORMATION

Why choose hubXchange?

 

FULL AGENDA

Click the topic titles to find out more!

Loading
08:00
  1. Registration
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
08:30
  1. 30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
09:05
  1. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
    Why many “best-in-class” binders still fail clinically The industry shift from affinity optimization toward systems-level biology and tissue selectivity Whether potency obsession has created blind spo ...
  2. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
    How have intracellular proteins historically been accessed by antibody therapeutics? How can intracellular proteins, when presented as pMHC, be targeted by TCR and TCR-mimicking antibody-based therape ...
  3. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
    Which developability assays are most informative for assessing candidates early on? -for stability, PK, high-concentration, immunogenicity, specificity, etc What are the most impactful in silico metho ...
  4. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    How is the ADC space continuing to grow, and why does it remain heavily focused on similar payload types? Which different payloads may have greater potential for patients who do not respond to establi ...
  5. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    The current payload landscape – a TOPO1i world Development of novel single and dual payloads. What should we be looking for? Fit-for-purpose – identifying optimal payloads for specific tumor indicatio ...
10:10
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
10:40
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
11:10
  1. Morning Refreshments
    10 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
11:20
  1. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
    Navigating vast sequence space: How can teams efficiently explore enormous antibody repertoires to pinpoint candidates with the right balance of affinity, specificity, and developability? Balancing po ...
  2. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
     How can molecular architecture be optimised to balance potency, stability and manufacturability? What strategies can reduce aggregation, chain mispairing and unwanted molecular interactions? How can ...
  3. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
     How can molecular architecture be optimised to balance potency, stability and manufacturability? What strategies can reduce aggregation, chain mispairing and unwanted molecular interactions? How can ...
  4. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    Optimization of Drug Antibody Conjugates: Defining DAR, linker kinetics and stability, structural features and compositional stoichiometry, and analytical robustness Identification of limitations to d ...
  5. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    How can we effectively identify the optimal payload–linker combinations to enhance the efficacy and safety of antibody-drug conjugates (ADCs)? What strategies can be employed to address and mitigate l ...
12:20
  1. Networking Lunch
    60 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
13:20
  1. Spotlight Presentation: Accelerating Antibody and Biologic Workflows with Chemically Aware Macromolecule Registration
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Track antibody and ADC programs by leveraging CDD Vault’s chemically aware macromolecule capabilities. Heavy- and light- chain sequences can be registered and structurally annotated with  domains, hin ...
13:50
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
14:20
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
14:50
  1. Afternoon Refreshments
    10 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
15:10
  1. Lead Identification & Optimization
    30 mins
    • Lead Identification & Optimization
    The PioneerTM Antibody Discovery Platform is Bio-Rad’s biotherapeutic antibody generation service, centered around the Pioneer Antibody Library—one of the largest functional Fab libraries (225 billion ...
  2. Formats & Scaffolds
    30 mins
    • Formats & Scaffolds
    Bi- and multi-specific antibodies offer new ways to engage complex disease biology, but greater functionality also introduces important therapeutic design challenges. This session will share practical ...
  3. Bi/Multispecifics
    30 mins
    • Bi/Multispecifics
    Bispecific antibodies (BsAbs) offer transformative therapeutic potential, but their complex, non-native structure creates production challenges such as mispairing, low yield, and purification difficul ...
  4. ADC Linker Design & Conjugation Technologies
    30 mins
    • ADC Linker Design & Conjugation Technologies
    A central challenge in drug development is determining whether a therapeutic achieves appropriate tissue distribution and produces biologically meaningful effects. We present a drug-inclusive spatial ...
  5. ADC Cytotoxic Payload
    30 mins
    • ADC Cytotoxic Payload
15:45
  1. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
    Strategies for improving antibody affinity during lead optimization. How does antibody affinity influence internalization, efficacy, and pharmacokinetics? To what extent do CDX and PDX models reflect ...
  2. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
    When you screen building blocks individually, what predicts (or fails to predict) how they'll behave once combined? How do you decide format before knowing your final pairing — or does format selectio ...
  3. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
    Why potent T-cell activation often comes at the cost of increased cytokine release. Strategies to improve the therapeutic window while maintaining robust antitumor efficacy. Challenges in translating ...
  4. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    How much of ADC linker selection is rational design versus platform default, and how rigorously are linker choices tested against alternatives? Are we over-indexing on linker chemistry rather than the ...
  5. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    Are topoisomerase I inhibitor (TOP1i) payloads the default for solid tumor ADCs, or is the field over-converging on a single payload class with shared toxicity, resistance, and sequencing liabilities? ...
16:45
  1. Drinks-Canape Reception
    60 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization

EVENT INFORMATION

3-featuredimage

DATES

San Francisco
Nov 3, 2026

Tuesday, 3rd November 2026

 

DoubleTree Princeton Hotel

 

VENUE

 

DoubleTree by Hilton San Francisco Airport Hotel

DoubleTree by Hilton Hotel Princeton
4355 US Route 1
Princeton, New Jersey 08540
United States

MAP

EVENT PARTNERS

4-featuredimage

EVENT PARTNERS

OUR MEDIA PARTNERS

5-featuredimage

REGISTRATION FORM - Register for free!

6-featuredimage

Complimentary Registration is only available for Senior Scientists & above, in Pharma & Bio Tech, with an active drug pipeline.
 

For Service Providers, please click here.